Loading...
Bilateral Trade Intelligence · $934 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $934 worth of pharmaceutical formulations from Luxembourg across 1 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are NEUNCO PHARMACEUTICAL B.V. ($934). The leading products are Tramadol ($934). Average shipment value: $934.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Tramadol | $934 | 100.0% |
India imports 1+ pharmaceutical formulations from Luxembourg with a combined trade value of $934. Key products include Tramadol ($934). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Luxembourg, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Luxembourg buyers, regulatory requirements, and logistics for that specific product corridor. Products include Tramadol ($934) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Luxembourg. Leading exporters include Neunco Pharmaceutical B.v., . The top exporter accounts for 100.0% of total India–Luxembourg pharma exports. Source: Indian Customs (DGFT).
1 companies in Luxembourg import pharmaceutical formulations from India. Top buyers include Aurobindo Pharma Ltd, . The largest buyer accounts for 100.0% of India–Luxembourg pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Luxembourg and India has remained relatively modest over the past decade. In 2024, Luxembourg's pharmaceutical exports to India were valued at approximately $8,300, indicating a niche presence in the Indian market. This figure underscores the limited scale of trade between the two nations in the pharmaceutical sector.
Luxembourg's contribution to India's pharmaceutical imports is minimal, accounting for a fraction of a percent of India's total pharmaceutical imports. The primary product imported from Luxembourg is Tramadol, a pain management medication, highlighting the specialized nature of Luxembourg's pharmaceutical exports to India.
Between 2024 and 2026, there have been no significant policy changes or trade agreements between Luxembourg and India affecting pharmaceutical imports. The regulatory frameworks governing pharmaceutical imports remain consistent, with the Central Drugs Standard Control Organisation (CDSCO) continuing to oversee the importation and approval processes.
Registration process, GMP requirements, import documentation
Luxembourg pharmaceutical companies seeking to export products to India must navigate the CDSCO registration process. This involves submitting an Integrated Registration Form (IRF) through the CDSCO's SUGAM portal, accompanied by necessary documents such as an undertaking form, valid address proof, and ID proof of the authorized person. The registration process is subject to verification by CDSCO Headquarters, and the grant of a Dual Use No Objection Certificate (NOC) is typically valid for one year.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure product quality and safety. Manufacturers must provide a Site Master File detailing their manufacturing processes and quality control measures. Additionally, a Certificate of Pharmaceutical Product (COPP) is required, attesting to the product's approval for sale in the country of origin.
To import pharmaceutical products into India, Luxembourg companies must obtain an import license (Form 10) from CDSCO. This process involves submitting the necessary registration certificates, a No Objection Certificate (NOC), and a test license. Customs procedures require compliance with CDSCO guidelines, including product testing and adherence to cold chain logistics to maintain product efficacy.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Luxembourg are concentrated in the analgesic category, with Tramadol being the sole product imported. This indicates a specialized trade relationship focused on specific therapeutic areas.
The import of Tramadol from Luxembourg suggests a demand for specific formulations not readily available in the Indian market. This reflects India's interest in sourcing specialized pharmaceutical products to meet diverse medical needs.
The importation of Tramadol from Luxembourg is driven by factors such as patent protection, quality standards, and the need to address specific therapeutic requirements within India. Luxembourg's adherence to stringent manufacturing practices and regulatory compliance makes its pharmaceutical products attractive to Indian buyers.
Tariff structure, trade agreements, IP and patent landscape
Pharmaceutical formulations imported into India are subject to the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. These duties are subject to change based on government policies and trade agreements.
As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Luxembourg that offer preferential duty rates for pharmaceutical imports. Trade relations are governed by standard international trade regulations without additional preferential treatment.
India's patent regime, including Section 3(d) and provisions for compulsory licensing, influences the importation of patented drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of imported drugs to ensure affordability and accessibility for the Indian population.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Luxembourg to India typically utilize major sea routes, with transit times varying based on the shipping method and specific ports of departure and arrival. Air freight options are also available, offering faster delivery times at higher costs.
Luxembourg's pharmaceutical exports to India are likely shipped through major European ports such as Rotterdam or Antwerp, which are equipped to handle pharmaceutical goods. In India, ports like Mumbai and Chennai are equipped to handle pharmaceutical imports, ensuring compliance with regulatory standards.
Upon arrival in India, pharmaceutical imports undergo customs clearance, which includes verification of documentation and compliance with CDSCO regulations. Products requiring cold chain storage are managed according to Good Distribution Practice (GDP) guidelines to maintain product integrity.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports specific drugs like Tramadol from Luxembourg to meet domestic demand for certain formulations not produced locally. This import dependency is influenced by factors such as patent protection, quality standards, and the need to address specific therapeutic requirements.
NEUNCO Pharmaceutical B.V. is the primary Luxembourg supplier exporting pharmaceutical products to India. Their strategy involves exporting specialized products to meet specific market needs within India.
India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing capabilities. While these efforts may reduce reliance on imports over time, the demand for specialized pharmaceutical products from countries like Luxembourg is expected to persist, maintaining a niche import market.
Competing origins, India's edge, challenges and threats
India imports pharmaceuticals from various countries, including the USA, EU nations, China, Switzerland, and Japan. Luxembourg's share in this import landscape is minimal compared to these major suppliers.
Luxembourg's pharmaceutical exports to India are characterized by high-quality standards, adherence to international regulatory requirements, and the provision of specialized products not readily available in the Indian market.
Indian manufacturers are increasingly developing alternatives to imported drugs, including biosimilars and generic versions, supported by initiatives like the PLI scheme. This domestic production may reduce the need for imports of certain pharmaceutical products over time.
India exported pharmaceuticals worth $934 to Luxembourg across 1 verified shipments.
1. NEUNCO PHARMACEUTICAL B.V. — $934. Total: 1 suppliers.
1. AUROBINDO PHARMA LTD — $934. 1 buyers total.
1. Tramadol ($934, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $934 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$934 per consignment across 1 shipments.
1 Indian companies. Largest: NEUNCO PHARMACEUTICAL B.V. with $934.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 1 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists